Skip to the main content

Original scientific paper

https://doi.org/10.20471/dec.2023.59.02.07

Correlations Between Clinical and Metabolic Variables and Smoking among Antipsychotic- Naïve First-Episode and Nonadherent Chronic Patients with Psychosis

Sergej Nadalin ; Department of Psychiatry, General Hospital “Dr. Josip Benčević”, Slavonski Brod, Croatia; School of Medicine, Catholic University of Croatia, Zagreb, Croatia,
Vjekoslav Peitl ; School of Medicine, Catholic University of Croatia, Zagreb, Croatia; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Dalibor Karlović ; School of Medicine, Catholic University of Croatia, Zagreb, Croatia; Department of Psychiatry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Sara Huskić ; Faculty of Dental Medicine, University of Rijeka, Rijeka, Croatia
Lena Zatković ; Hospital pharmacy, Clinical Hospital Center Rijeka, Rijeka, Croatia
Alena Buretić-Tomljanović ; Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia


Full text: english pdf 393 Kb

page 241-250

downloads: 175

cite


Abstract

An interaction between smoking and antipsychotic medications could potentially affect treatment efficacy and promote metabolic side effects. We investigated the contribution of smoking status towards Positive and Negative Syndrome Scale (PANSS) scores and metabolic syndrome- related parameters (plasma lipid and glucose concentrations, and body mass index) among two groups of unmedicated patients with psychosis from the Croatian population: antipsychotic-naïve first-episode patients and nonadherent chronic patients. Previous data are inconsistent regarding the effects of smoking on clinical psychopathology among antipsychotic-naïve or minimally medicated patients with first-episode psychosis, and no studies have examined the potential influence of smoking on clinical psychopathology and metabolic parameters among nonadherent patients with chronic psychosis. Information about smoking status and antipsychotic nonadherence was obtained via auto-anamnestic and hetero-anamnestic information. PANSS data were obtained while patients were in a psychotic state during the illness requiring hospitalization. Plasma total cholesterol, LDL cholesterol, HDL cholesterol (HDL- c), triglyceride, and glucose levels were determined after a 12-hour fasting period. Compared with non-smoking antipsychotic-naïve first-episode individuals, antipsychotic-naïve smokers exhibited significantly lower depression factor scores, and significantly higher triglyceride levels and triglyceride/HDL- c ratio (p < 0.05). Compared with non-smoking nonadherent chronic individuals, nonadherent smokers exhibited significantly lower negative symptoms and negative factor scores, and lower HDL- c levels. Contributions of smoking to clinical and metabolic parameters ranged from ~ 3.4 % to 10 %. Our present results indicated that smoking may be associated with less severe clinical psychopathology, and with increased risk for metabolic abnormalities, among unmedicated patients with first-episode psychosis and chronic psychosis.

Keywords

medication adherence; psychotic disorders; schizophrenia; smoking

Hrčak ID:

304154

URI

https://hrcak.srce.hr/304154

Publication date:

19.6.2023.

Visits: 443 *